Log In
Print this Print this

biosimilar omalizumab (STI-004)

  Manage Alerts
Collapse Summary General Information
Company Mabtech Ltd.
DescriptionBiosimilar of omalizumab, a humanized mAb against immunoglobulin E (IgE)
Molecular Target IgE
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II/III
Standard IndicationAsthma
Indication DetailsTreat allergic asthma; Treat asthma
Regulatory Designation
PartnerSorrento Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today